Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00649896 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT00649896 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 76 participants.
The verdict
NCT00649896, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
The primary objective of this study was to compare the adhesive quality of a new formulation of the Mylan Estradiol Transdermal System with that of Climara® Transdermal System following a single system application in 80 healthy postmenopausal female volunteers. As a secondary objective, primary dermal irritation was assessed after removal of each transdermal system.
Interventions
- DRUG Mylan Estradiol Transdermal System 0.025 mg/day
- DRUG Climara® Transdermal System 0.025 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2003-08 |
| Est. Completion | 2003-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00649896
The ClinicalTrials.gov registry entry for NCT00649896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mylan Estradiol Transdermal System 0.025 mg/day is the first listed.
NCT00649896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00649896 about?
NCT00649896 is a clinical study titled "Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day". The primary objective of this study was to compare the adhesive quality of a new formulation of the Mylan Estradiol Transdermal System with that of Climara® Transdermal System following a single system application in 80 healthy postmenopausal female volunteers. As a secondary objective, primary derm...
What is the current status of trial NCT00649896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2003-08. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00649896?
The interventions under investigation include: Mylan Estradiol Transdermal System 0.025 mg/day (DRUG), Climara® Transdermal System 0.025 mg/day (DRUG).
Who is sponsoring clinical trial NCT00649896?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.